GlassScriptPhysician profile
Akwasi A Sefa
NPI 1437143757
$6,481.13
in general payments reported to CMS, 2019-2025
42 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,591 · 2020: $206 · 2021: $170 · 2022: $967 · 2023: $1,112 · 2024: $1,151 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,408.48 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $935.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $550.51 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $450.87 | 2019-2025 | |
| Valeritas, INC. | $351.94 | 2019 | |
| Lilly USA, LLC | $313.36 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $265.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $204.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $201.59 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.76 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.87 | 2019-2023 | Trulance, Xifaxan |
| Ascensia Diabetes Care US INC. | $152.90 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.83 | 2024-2025 | Caplyta |
| Ardelyx, INC. | $107.59 | 2023-2025 | Ibsrela |
| Leo Pharma INC. | $102.34 | 2023-2025 | Adbry, Anzupgo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $83.09 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $79.01 | 2022-2024 | Verquvo, Dificid, Belsomra |
| Daiichi Sankyo INC. | $78.62 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $70.97 | 2020-2024 | Myrbetriq, Veozah |
| Dexcom, INC. | $66.87 | 2019-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $61.87 | 2022-2024 | Minimed 780g |
| Abbott Laboratories | $47.38 | 2024 | Freestyle Libre 3 |
| Almatica Pharma LLC | $47.08 | 2024 | Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $46.99 | 2025 | Zoryve |
| Lundbeck LLC | $42.11 | 2025 | Rexulti |
| Hikma Pharmaceuticals USA | $39.60 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.00 | 2019 | |
| Viiv Healthcare Company | $23.82 | 2025 | Apretude |
| Corium, LLC | $23.24 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $23.18 | 2019-2020 | |
| Pfizer INC. | $21.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.28 | 2022 | |
| Cequr Corporation | $19.00 | 2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $18.69 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $17.18 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $16.97 | 2019 | |
| Biogen, INC. | $15.75 | 2020 | |
| Corcept Therapeutics | $15.46 | 2023 | Korlym |
| Circassia INC. | $15.26 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.70 | 2023 | Givlaari |
| Allergan, INC. | $13.17 | 2019 | |
| Electromed, INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akwasi Sefa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.